RCCI is actively engaged with corporations and CROs who believe as we do in the importance of diversity in clinical trials to accurately determine the safety and efficacy of new drugs and devices. The Division understands the unique positions RCMI grantee institutions occupy in this effort. We have two ways to engage institutions, which are interested in industry clinical trials. The goal is to bring additional opportunities to participate in essential trials to eliminate health disparities.